年龄相关眼病研究2中CFH或ARMS2与ω-3脂肪酸、低剂量与高剂量锌或β-胡萝卜素与叶黄素和玉米黄素对年龄相关性黄斑变性进展的交互作用:年龄相关眼病研究2报告第18号
本研究为AREDS2随机试验的事后分析,纳入4203名白人参与者,评估CFH和ARMS2基因型是否修饰口服营养素对年龄相关性黄斑变性(AMD)进展的疗效。结果显示ARMS2风险等位基因与晚期AMD和新生血管性AMD进展显著相关,但基因型未显著修饰任何AREDS2补充剂的反应。
要点
- ARMS2风险等位基因与晚期AMD进展显著相关(P=2.40×10-5),与新生血管性AMD也显著相关(P=0.002)。
- CFH风险等位基因与AMD进展无显著关联。
- 基因型未显著修饰对任何AREDS2补充剂的反应。
核心结论
- CFH和ARMS2风险等位基因不修饰AREDS2营养素补充剂对晚期AMD(地图样萎缩和新生血管性AMD)进展的反应。
研究设计与样本
- AREDS2随机试验的事后分析,纳入4203名白人参与者,双眼大玻璃膜疣或单眼晚期AMD,随机分配至叶黄素和玉米黄素、ω-3脂肪酸、两者联合或安慰剂,多数同时接受AREDS补充剂;二次随机评估改良AREDS补充剂4个治疗组:较低锌剂量、省略β-胡萝卜素、两者兼有或未改良。
- 对CFH的rs1061170和ARMS2的rs10490924单核苷酸多态性进行基因分型。
- 使用双变量脆弱模型分析双眼,包含基因-补充剂交互项,并调整年龄、性别、教育水平和吸烟状态。
主要发现
- 完整数据 available 于2775只无基线晚期AMD的眼(1684名参与者),平均年龄±标准差72.1±7.7岁,女性占58.5%,中位随访5年。
- ARMS2风险等位基因与晚期AMD进展显著相关(P=2.40×10-5),与新生血管性AMD也显著相关(P=0.002),与任何地图样萎缩无显著关联(P=0.097)。
- CFH风险等位基因与AMD进展无显著关联。
- 基因型未显著修饰对任何AREDS2补充剂的反应。
关键数值与推荐
- ARMS2风险等位基因与晚期AMD进展显著相关(P=2.40×10-5),与新生血管性AMD显著相关(P=0.002),与任何地图样萎缩无显著关联(P=0.097)。
- CFH风险等位基因与AMD进展无显著关联。
- 基因型与任何AREDS2补充剂的交互作用均未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether genotypes at 2 major loci associated with age-related macular degeneration (AMD), complement factor H (CFH), or age-related maculopathy susceptibility 2 (ARMS2), modify the response to oral nutrients for the treatment of AMD in the Age-Related Eye Disease Study 2 (AREDS2). DESIGN: Post hoc analysis of a randomized trial. PARTICIPANTS: White AREDS2 participants. METHODS: AREDS2 participants (n = 4203) with bilateral large drusen or late AMD in 1 eye were assigned randomly to lutein and zeaxanthin, omega-3 fatty acids, both, or placebo, and most also received the AREDS supplements. A secondary randomization assessed modified AREDS supplements in 4 treatment arms: lower zinc dosage, omission of β-carotene, both, or no modification. To evaluate the progression to late AMD, fundus photographs were obtained at baseline and annual study visits, and history of treatment for late AMD was obtained at study visits and 6-month interim telephone calls. Participants were genotyped for the single-nucleotide polymorphisms rs1061170 in CFH and rs10490924 in ARMS2. Bivariate frailty models using both eyes were conducted, including a gene-supplement interaction term and adjusting for age, gender, level of education, and smoking status. The main treatment effects, as well as the direct comparison between lutein plus zeaxanthin and β-carotene, were assessed for genotype interaction. MAIN OUTCOME MEASURES: The interaction between genotype and the response to AREDS2 supplements regarding progression to late AMD, any geographic atrophy (GA), and neovascular AMD. RESULTS: Complete data were available for 2775 eyes without baseline late AMD (1684 participants). The participants (mean age ± standard deviation, 72.1±7.7 years; 58.5% female) were followed up for a median of 5 years. The ARMS2 risk allele was associated significantly with progression to late AMD and neovascular AMD (P = 2.40 × 10-5 and P = 0.002, respectively), but not any GA (P = 0.097). The CFH risk allele was not associated with AMD progression. Genotype did not modify significantly the response to any of the AREDS2 supplements. CONCLUSIONS: CFH and ARMS2 risk alleles do not modify the response to the AREDS2 nutrient supplements with respect to the progression to late AMD (GA and neovascular AMD).
引用
- van Asten F, Chiu CY, Agrón E, et al. No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18. Ophthalmology. 2019. PMID: 31358387. doi:10.1016/j.ophtha.2019.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。